
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva Inc. is positioned for substantial revenue growth, particularly with the introduction of Giapreza, which addresses the critical unmet need in septic and distributive shock management, supported by updated treatment guidelines and a growing patient population. The recent launch of Xacduro has shown a remarkable sales trajectory, with forecasts indicating a leap from $2.0 million in 2023 to $95.3 million by 3Q25, reflecting the product's strong market acceptance and significant potential in the critical care sector. Additionally, the company's overall product sales have demonstrated impressive year-over-year growth rates, fostering a solid foundation for Innoviva’s expanding commercial momentum and profitability.
Bears say
Innoviva Inc faces considerable risks that may adversely impact its financial performance, including substantial mortality rates associated with MRSA infections, which complicates the treatment landscape for its critical care assets. Additionally, there are multiple uncertainties surrounding the successful commercialization of its marketed products and the timely launch of new treatments like ZEVTERA and zoliflodacin, all of which could hinder revenue growth. Furthermore, potential declines in royalty revenue from respiratory-focused products due to generic erosion, alongside macroeconomic factors and partnership risks, introduce further challenges to Innoviva's financial stability.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares